oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-1-116-123oncotomsk-969Research ArticleОБЗОРЫREVIEWSАсцит как предмет исследований при раке яичниковAscites as a subject of studies in ovarian cancerhttps://orcid.org/0000-0002-2773-1917ВиллертА. Б.VillertA. B.

Виллерт Алиса Борисовна, кандидат медицинских наук, старший научный сотрудник отделения онкогинекологии. SPIN‐код: 1975‐0042. Researcher ID (WOS): J‐3140‐2017. Author ID (Scopus): 56626547700.

г. Томск, 634009, пер. Кооперативный, 5.

Alisa B. Villert, MD, PhD, Senior Researcher. Researcher ID (WOS): J‐3140‐2017. Author ID (Scopus): 56626547700.

5, Kooperativny Street, 634009-Tomsk

avillert@yandex.ruhttps://orcid.org/0000-0002-6854-8940КоломиецЛ. А.KolomietsL. A.

Коломиец Лариса Александровна, доктор медицинских наук, профессор, заведующая отделением онкогинекологии.SPIN‐код: 6316‐1146. Researcher ID (WOS): C‐8573‐2012. Author ID (Scopus): 7004921120.

г. Томск, 634009, пер. Кооперативный, 5;г. Томск, 634050, Московский тракт, 2.

Larisa A. Kolomiets, MD, DSc, Professor, Head of Gynecological Oncology Department.Researcher ID (WOS): C‐8573‐2012. Author ID (Scopus): 7004921120.

5, Kooperativny Street, 634009-Tomsk;2, Moskovsky trakt, Tomsk-634050

kolomietsla@oncology.tomsk.ruhttps://orcid.org/0000-0003-4595-4177ЮнусоваН. В.YunusovaN. V.

Юнусова Наталья Валерьевна, доктор медицинских наук, ведущий научный сотрудник лаборатории биохимии опухолеиu.SPIN‐код: 3513‐1888. Researcher ID (WOS): C‐9275‐ 2012. Author ID (Scopus): 8354141400.

г. Томск, 634009, пер. Кооперативный, 5;г. Томск, 634050, Московский тракт, 2.

Natalia V. Yunusova, DSc, Leading Researcher. Researcher ID (WOS): C‐9275‐2012. Author ID (Scopus): 8354141400.

5, Kooperativny Street, 634009-Tomsk;2, Moskovsky trakt, Tomsk-634050

bochkarevanv@oncology.tomsk.ruИвановаА. А.IvanovaA. A.

Иванова Анна Александровна, кандидат медицинский наук, врач клинической лабораторной диагностики.

г. Томск, 634009, пер. Кооперативный, 5;

Anna A. Ivanova, MD, PhD, Clinical Diagnostic Laboratory.

5, Kooperativny Street, 634009-Tomsk

ivanovaaa@oncology.tomsk.ruНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университетРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityRussian Federation201928022019181116123Copyright © Виллерт А.Б., Коломиец Л.А., Юнусова Н.В., Иванова А.А., 20192019Виллерт А.Б., Коломиец Л.А., Юнусова Н.В., Иванова А.А.Villert A.B., Kolomiets L.A., Yunusova N.V., Ivanova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/969

Рак яичников (РЯ) представляет собой неоднородную группу опухолей, различающихся этиологией и клиническим течением. Наиболее часто встречающийся гистотип – High-grade серозный рак яичников, который в большинстве случаев диагностируется на диссеминированной стадии и сопровождается асцитом. Перитонеальная диссеминация является одним из наиболее неблагоприятных факторов прогрессирования злокачественных опухолей. Наличие асцита увеличивает точность ультрасонографической диагностики канцероматоза. Однако прогностические факторы, связанные с злокачественным асцитом при раке яичников, изучены недостаточно. Среди клинических параметров наибольшую прогностическую информацию несет количество асцитической жидкости – малоасцитные раки обладают более благоприятным лечебным прогнозом и взаимосвязаны с рядом иммунологических особенностей, позволяющих вынести их в отдельную подгруппу. Асцитическая жидкость является легкодоступным и ценным источником клеточного и внеклеточного компонентов, задействованных в овариальном канцерогенезе. Среди растворимых высокои низкомолекулярных компонентов асцита ведется активный поиск дополнительных прогностических и предикторных факторов, позволяющих уточнить молекулярный фенотип рака и персонифицировать лечение больных РЯ.

Ovarian cancer is a highly heterogeneous disease characterized by multiple histological subtypes. High- grade serous ovarian carcinoma is the most common histological subtype of ovarian cancer. The majority of ovarian cancer patients present with malignant ascites at diagnosis. Peritoneal dissemination is one of the most unfavorable factors for tumor progression and recurrence. A more precise visualization of peritoneal carcinomatosis can be achieved by transabdominal ultrasound. However, the prognostic factors associated with malignant ascites in ovarian cancer are currently not well understood. Among the clinical parameters, the volume of ascites has the greatest information in terms of prognosis of disseminated ovarian cancer. Ovarian cancer with small-volume ascites has a more favorable therapeutic prognosis. Ascites is an easily accessible and valuable source of cellular and extracellular components contained in it that are involved in ovarian carcinogenesis. Ascites represents an accessible and valuable source of material to identify signals that influence tumor growth. At present, among the soluble high- and low molecular components of ascites, an active search for additional prognostic and predictor factors is being conducted, providing insights into the molecular mechanisms for clinical phenotypes of ovarian cancer.

асцитрак яичниковвизуализациякомпоненты асцитапрогнозпатогенезмезотелиальные клеткиперитонеальный канцерогенезультразвуковое исследованиеиммуноцитохимияascitesovarian cancervisualizationascite componentsprognosispathogenesismesothelial cellsperitoneal carcinogenesisultrasoundimmunocytochemistryReferencesRunyon B.A. Care of patients with ascites. N Engl J Med. 1994 Feb 3; 330 (5): 337–42. doi: 10.1056/NEJM199402033300508.Runyon B.A. Care of patients with ascites. N Engl J Med. 1994 Feb 3; 330 (5): 337–42. doi: 10.1056/NEJM199402033300508.Runyon B.A., Hoefs J.C., Morgan T.R. Ascitic fluid analysis in malignancy‐related ascites. Hepatology. 1988; 8: 1104–1109.Runyon B.A., Hoefs J.C., Morgan T.R. Ascitic fluid analysis in malignancy‐related ascites. Hepatology. 1988; 8: 1104–1109.Jehn C.F., Küpferling S., Oskay-Özcelik G., Lüftner D. A survey of treatment approaches of malignant ascites in Germany and Austria. Support Care Cancer. 2015 Jul; 23 (7): 2073–8. doi: 10.1007/s00520‐014‐2557‐9.Jehn C.F., Küpferling S., Oskay-Özcelik G., Lüftner D. A survey of treatment approaches of malignant ascites in Germany and Austria. Support Care Cancer. 2015 Jul; 23 (7): 2073–8. doi: 10.1007/s00520‐014‐2557‐9.Parsons S.L., Lang M.W., Steele R.J. Malignant ascites: a 2‐year review from a teaching hospital. Eur. J. Surg. Oncol. 1996; 22: 237–239.Parsons S.L., Lang M.W., Steele R.J. Malignant ascites: a 2‐year review from a teaching hospital. Eur. J. Surg. Oncol. 1996; 22: 237–239.Smolle E., Taucher V., Haybaeck J. Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. Anticancer Res. 2014 Apr; 34 (4): 1553–61.Smolle E., Taucher V., Haybaeck J. Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. Anticancer Res. 2014 Apr; 34 (4): 1553–61.Kipps Е., Tan D.S.P., Kayе S.B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013 Apr; 13 (4): 273–82. doi: 10.1038/nrc3432.Kipps Е., Tan D.S.P., Kayе S.B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013 Apr; 13 (4): 273–82. doi: 10.1038/nrc3432.Starling E.H. On the absorption of fluids from the connective tissue spaces. J Physiol. 1896 May 5; 19 (4): 312–26.Starling E.H. On the absorption of fluids from the connective tissue spaces. J Physiol. 1896 May 5; 19 (4): 312–26.Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25; 219 (4587): 983–5.Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25; 219 (4587): 983–5.Степанов И.В., Падеров Ю.М., Афанасьев С.Г. Перитонеальный канцероматоз. Сибирский онкологический журнал. 2014; 5: 45–53. [Stepanov I.V., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; 5: 45–53. (in Russian)].Степанов И.В., Падеров Ю.М., Афанасьев С.Г. Перитонеальный канцероматоз. Сибирский онкологический журнал. 2014; 5: 45–53. [Stepanov I.V., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; 5: 45–53. (in Russian)].European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep; 53 (3): 397–417. doi: 10.1016/j.jhep.2010.05.004.European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep; 53 (3): 397–417. doi: 10.1016/j.jhep.2010.05.004.Ивашкин В.Т. Гастроэнтерология: национальное руководство. М., 2008. 704. [Ivashkin V.T. Gastroenterology: National Guideline. Mos‐ cow, 2008. 704. (in Russian)].Ивашкин В.Т. Гастроэнтерология: национальное руководство. М., 2008. 704. [Ivashkin V.T. Gastroenterology: National Guideline. Mos‐ cow, 2008. 704. (in Russian)].Ардатская М.Д. Асцит и перитонит в практике терапевта и гастроэнтеролога. Consilium Medicum. 2009; 11 (8): 51–60. [Ardatskaya M.D. Ascites and peritonitis in the practice of therapist and gastro‐ enterologist. Consilium Medicum. 2009; 11 (8): 51–60. (in Russian)].Ардатская М.Д. Асцит и перитонит в практике терапевта и гастроэнтеролога. Consilium Medicum. 2009; 11 (8): 51–60. [Ardatskaya M.D. Ascites and peritonitis in the practice of therapist and gastro‐ enterologist. Consilium Medicum. 2009; 11 (8): 51–60. (in Russian)].Inadomi J., Cello J.P., Koch J. Ultrasonographic determination of ascitic volume. Hepatology. 1996 Sep; 24 (3): 549–51. doi:10.1002/ hep.510240314.Inadomi J., Cello J.P., Koch J. Ultrasonographic determination of ascitic volume. Hepatology. 1996 Sep; 24 (3): 549–51. doi:10.1002/ hep.510240314.Болдогоева И.М., Берзин С.А. Современные возможности диагностики рака яичников в онкологическом диспансере. Екатеринбург, 2007: 34–52. [Boldogoyeva I.M., Berzin S.A. Modern possibilities of diagnosis of ovarian cancer in the oncologic dispensary. Yekaterinburg, 2007. 34–52. (in Russian)].Болдогоева И.М., Берзин С.А. Современные возможности диагностики рака яичников в онкологическом диспансере. Екатеринбург, 2007: 34–52. [Boldogoyeva I.M., Berzin S.A. Modern possibilities of diagnosis of ovarian cancer in the oncologic dispensary. Yekaterinburg, 2007. 34–52. (in Russian)].Синицина М.Е., Чекалова М.А., Брюзгин В.В., Махова Е.Е. Место эхографии в уточнении подходов к лечению рака яичников. Опухоли женской репродуктивной системы. 2008; 4: 72–76. [Sinitsina M.Ye., Chekalova M.A., Bryuzgin V.V., Makhova Ye.Ye. Place of echography in specifying approaches to treating ovarian cancer. Tumors of female reproductive system. 2008; 4: 72–76. (in Russian)].Синицина М.Е., Чекалова М.А., Брюзгин В.В., Махова Е.Е. Место эхографии в уточнении подходов к лечению рака яичников. Опухоли женской репродуктивной системы. 2008; 4: 72–76. [Sinitsina M.Ye., Chekalova M.A., Bryuzgin V.V., Makhova Ye.Ye. Place of echography in specifying approaches to treating ovarian cancer. Tumors of female reproductive system. 2008; 4: 72–76. (in Russian)].Степанов С.О., Митина Л.А., Гуц О.В., Беспалов П.Д. Визуализация перитонеальной диссеминации при ультразвуковом исследовании. Лучевая диагностика и терапия. 2013; 3 (4): 66–70. [Stepanov S.O., Mitina L.A., Guts O.V., Bespalov P.D. Ultrasound imaging of peritoneal dissemination. Diagnostic radiology and radiotherapy. 2013; 3 (4): 66–70. (in Russian)].Степанов С.О., Митина Л.А., Гуц О.В., Беспалов П.Д. Визуализация перитонеальной диссеминации при ультразвуковом исследовании. Лучевая диагностика и терапия. 2013; 3 (4): 66–70. [Stepanov S.O., Mitina L.A., Guts O.V., Bespalov P.D. Ultrasound imaging of peritoneal dissemination. Diagnostic radiology and radiotherapy. 2013; 3 (4): 66–70. (in Russian)].Вяткина Н.В., Фролова И.Г., Коломиец Л.А., Молчанов С.В., Виллерт А.Б. Возможности комплексного ультразвукового исследо‐ вания в дооперационном стадировании диссеминированного рака яичников. Сибирский онкологический журнал. 2016; 15 (4): 26–32. [Vyatkina N.V., Frolova I.G., Kolomiets L.A., Molchanov S.V., Villert А.B. Diagnostic value of ultrasound examination in preoperative staging of disseminated ovarian cancer. Siberian journal of oncology. 2016; 15 (4): 26–32. (in Russian)]. doi: 10.21294/1814‐4861‐2016‐15‐4‐26‐32.Вяткина Н.В., Фролова И.Г., Коломиец Л.А., Молчанов С.В., Виллерт А.Б. Возможности комплексного ультразвукового исследо‐ вания в дооперационном стадировании диссеминированного рака яичников. Сибирский онкологический журнал. 2016; 15 (4): 26–32. [Vyatkina N.V., Frolova I.G., Kolomiets L.A., Molchanov S.V., Villert А.B. Diagnostic value of ultrasound examination in preoperative staging of disseminated ovarian cancer. Siberian journal of oncology. 2016; 15 (4): 26–32. (in Russian)]. doi: 10.21294/1814‐4861‐2016‐15‐4‐26‐32.Mackey J.R., Venner P.M. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996; 6: 474–480.Mackey J.R., Venner P.M. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996; 6: 474–480.Ayantunde A.A., Parsons S.L. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945–949. doi: 10.1093/annonc/mdl499.Ayantunde A.A., Parsons S.L. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945–949. doi: 10.1093/annonc/mdl499.Garrison R.N., Kaelin L.D., Galloway R.H., Heuser L.S. Ma‐ lignant ascites. Clinical and experimental observations. Ann Surg 1986; 203: 644–651.Garrison R.N., Kaelin L.D., Galloway R.H., Heuser L.S. Ma‐ lignant ascites. Clinical and experimental observations. Ann Surg 1986; 203: 644–651.Sangisetty S.L., Miner T.J. Malignant ascites: A review of prognos‐ tic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 2012 April 27; 4 (4): 87–95. doi: 10.4240/wjgs.v4.i4.87.Sangisetty S.L., Miner T.J. Malignant ascites: A review of prognos‐ tic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 2012 April 27; 4 (4): 87–95. doi: 10.4240/wjgs.v4.i4.87.Szender J.B., Emmons T., Belliotti S., Dickson D., Khan A., Morrell K., Khan A.N.M.N., Singel K.L., Mayor P.C., Moysich K.B., Odunsi K., Segal B.H., Eng K.H. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 2017 Sep; 146 (3): 491–497. doi: 10.1016/j. ygyno.2017.06.008.Szender J.B., Emmons T., Belliotti S., Dickson D., Khan A., Morrell K., Khan A.N.M.N., Singel K.L., Mayor P.C., Moysich K.B., Odunsi K., Segal B.H., Eng K.H. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 2017 Sep; 146 (3): 491–497. doi: 10.1016/j. ygyno.2017.06.008.Tan D.S., Agarwal R., Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 7 (11): 939–1. doi: 10.1016/S1470‐2045(06)70939‐1.Tan D.S., Agarwal R., Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 7 (11): 939–1. doi: 10.1016/S1470‐2045(06)70939‐1.Lazarov N., Lazarov L., Lazarov S. Role of ascites and peritoneal cytology as prognostic factor for a patients with early epithelial ovarian cancer. Trakia Journal of Sciences. 2013; 11 (4): 359–361.Lazarov N., Lazarov L., Lazarov S. Role of ascites and peritoneal cytology as prognostic factor for a patients with early epithelial ovarian cancer. Trakia Journal of Sciences. 2013; 11 (4): 359–361.Chan J.K., Tian C., Monk B.J., Herzog T., Kapp D.S., Bell J., Young R.C.; Gynecologic Oncology Group. Prognostic factors for high‐ risk early‐stage epithelial ovarian cancer. Cancer. 2008 May 15; 112 (10): 2202–10. doi: 10.1002/cncr.23390.Chan J.K., Tian C., Monk B.J., Herzog T., Kapp D.S., Bell J., Young R.C.; Gynecologic Oncology Group. Prognostic factors for high‐ risk early‐stage epithelial ovarian cancer. Cancer. 2008 May 15; 112 (10): 2202–10. doi: 10.1002/cncr.23390.Kolomainen D.F., A’Hern R., Coxon F.Y., Fisher C., King D.M., Blake P.R., Barton D.P., Shepherd J.H., Kaye S.B., Gore M.E. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol. 2003; 21 (16): 3113–8. doi: 10.1200/JCO.2003.06.119.Kolomainen D.F., A’Hern R., Coxon F.Y., Fisher C., King D.M., Blake P.R., Barton D.P., Shepherd J.H., Kaye S.B., Gore M.E. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol. 2003; 21 (16): 3113–8. doi: 10.1200/JCO.2003.06.119.Puls L.E., Duniho T., Hunter J.E., Kryscio R., Blackhurst D., Gallion H. The Prognostic Implication of Ascites in Advanced‐Stage Ovarian Cancer. Gynecol Oncol. 1996 Apr; 61 (1): 109–12.Puls L.E., Duniho T., Hunter J.E., Kryscio R., Blackhurst D., Gallion H. The Prognostic Implication of Ascites in Advanced‐Stage Ovarian Cancer. Gynecol Oncol. 1996 Apr; 61 (1): 109–12.Feigenberg T., Clarke B., Virtanen C., Plotkin A., Letarte M., Rosen B., Bernardini M.Q., Kollara A., Brown T.J., Murphy K.J. Molecu‐ lar profiling and clinical outcome of high‐Grade serous ovarian cancer presenting with low‐versus high‐volume ascites. Biomed Res Int. 2014; 2014: 367103. doi: 10.1155/2014/367103.Feigenberg T., Clarke B., Virtanen C., Plotkin A., Letarte M., Rosen B., Bernardini M.Q., Kollara A., Brown T.J., Murphy K.J. Molecu‐ lar profiling and clinical outcome of high‐Grade serous ovarian cancer presenting with low‐versus high‐volume ascites. Biomed Res Int. 2014; 2014: 367103. doi: 10.1155/2014/367103.Kim S., Kim B., S. Song Y. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016 Sep; 107 (9): 1173–8. doi: 10.1111/cas.12987.Kim S., Kim B., S. Song Y. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016 Sep; 107 (9): 1173–8. doi: 10.1111/cas.12987.Latifi A., Luwor R.B., Bilandzic M., Nazaretian S., Stenvers K., Pyman J., Zhu H., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012; 7 (10): e46858. doi: 10.1371/journal.pone.0046858.Latifi A., Luwor R.B., Bilandzic M., Nazaretian S., Stenvers K., Pyman J., Zhu H., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012; 7 (10): e46858. doi: 10.1371/journal.pone.0046858.Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spher‐ oids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009 Apr; 113 (1): 143–8. doi: 10.1016/j.ygyno.2008.11.032.Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spher‐ oids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009 Apr; 113 (1): 143–8. doi: 10.1016/j.ygyno.2008.11.032.Naora H., Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005 May; 5 (5): 355–66. doi: 10.1038/nrc1611.Naora H., Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005 May; 5 (5): 355–66. doi: 10.1038/nrc1611.Ahmed N., Thompson E.W., Quinn M.A. Epithelial‐mesenchymal interconversions in normal ovarian surface epithelium and ovarian carci‐ nomas: an exception to the norm. J Cell Physiol. 2007; 213 (3): 581–8. doi: 10.1002/jcp.21240.Ahmed N., Thompson E.W., Quinn M.A. Epithelial‐mesenchymal interconversions in normal ovarian surface epithelium and ovarian carci‐ nomas: an exception to the norm. J Cell Physiol. 2007; 213 (3): 581–8. doi: 10.1002/jcp.21240.Stanojevic Z., Rancic G., Radic S., Potic-Zecevic N., Dorðevic B., Markovic M., Todorovska I. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol 2004; 12 (2): 115–8.Stanojevic Z., Rancic G., Radic S., Potic-Zecevic N., Dorðevic B., Markovic M., Todorovska I. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol 2004; 12 (2): 115–8.Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spher‐ oids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009 Apr; 113 (1): 143–8. doi: 10.1016/j.ygyno.2008.11.032.Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spher‐ oids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009 Apr; 113 (1): 143–8. doi: 10.1016/j.ygyno.2008.11.032.Ho C.M., Chang S.F., Hsiao C.C., Chien T.Y., Shih D.T. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J Biomed Sci. 2012 Feb 14; 19: 23. doi: 10.1186/1423‐0127‐19‐23.Ho C.M., Chang S.F., Hsiao C.C., Chien T.Y., Shih D.T. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J Biomed Sci. 2012 Feb 14; 19: 23. doi: 10.1186/1423‐0127‐19‐23.Ahmed N., Stenvers K.L. Getting to know ovarian cancer ascites: opportunities for targeted therapy‐based translational research. Front Oncol. 2013 Sep 25; 3: 256. doi: 10.3389/fonc.2013.00256.Ahmed N., Stenvers K.L. Getting to know ovarian cancer ascites: opportunities for targeted therapy‐based translational research. Front Oncol. 2013 Sep 25; 3: 256. doi: 10.3389/fonc.2013.00256.Wintzell M., Hijerpe E., Avall Lundqvist E., Shoshan M. Protein markers of cancer‐associated fibroblasts and tumor‐initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer. 2012 Aug 18; 12: 359. doi: 10.1186/1471‐2407‐12‐359.Wintzell M., Hijerpe E., Avall Lundqvist E., Shoshan M. Protein markers of cancer‐associated fibroblasts and tumor‐initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer. 2012 Aug 18; 12: 359. doi: 10.1186/1471‐2407‐12‐359.Guo L., Guo N. Exosomes: potent regulators of tumor malignancy and potential bio‐tools in clinical application. Crit Rev Oncol Hematol. 2015 Sep; 95 (3): 346–58. doi: 10.1016/j.critrevonc.2015.04.002.Guo L., Guo N. Exosomes: potent regulators of tumor malignancy and potential bio‐tools in clinical application. Crit Rev Oncol Hematol. 2015 Sep; 95 (3): 346–58. doi: 10.1016/j.critrevonc.2015.04.002.Halkia E., Chrelias G., Chrelias C., Esquivel J. Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal‐Treatment Con‐ siderations. Gastroenterol Res Pract. 2018 Apr 5; 2018: 5284814. doi: 10.1155/2018/5284814.Halkia E., Chrelias G., Chrelias C., Esquivel J. Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal‐Treatment Con‐ siderations. Gastroenterol Res Pract. 2018 Apr 5; 2018: 5284814. doi: 10.1155/2018/5284814.Janagam C., Atla B. Study of ascitic fluid cytology in ovarian tumors. Int J Res Med Sci. 2017 Dec; 5 (12): 5227–31. doi: 10.18203/2320‐ 6012.ijrms20175382.Janagam C., Atla B. Study of ascitic fluid cytology in ovarian tumors. Int J Res Med Sci. 2017 Dec; 5 (12): 5227–31. doi: 10.18203/2320‐ 6012.ijrms20175382.Юнусова Н.В., Тамкович С.Н., Кондакова И.В. Экзосомы в раз‐ личных биологических жидкостях: состав и функции. Молекулярная медицина. 2017; 15 (4): 14–22. [Yunusova N.V., Tamkovich S.N., Kondakova I.V. Exosomes from various biological fluids: pattern and function. Molecular medicine. 2017; 15 (4): 14–22. (in Russian)].Юнусова Н.В., Тамкович С.Н., Кондакова И.В. Экзосомы в раз‐ личных биологических жидкостях: состав и функции. Молекулярная медицина. 2017; 15 (4): 14–22. [Yunusova N.V., Tamkovich S.N., Kondakova I.V. Exosomes from various biological fluids: pattern and function. Molecular medicine. 2017; 15 (4): 14–22. (in Russian)].Yunusova N.V., Tamkovich S.N., Stakheeva M.N., Grigor’eva A.A., Somov A.K., Tugutova E.A., Kolomiets L.A., Molchanov S.V., Afanas’ev S.G., Kakurina G.V., Choinzonov E.L., Kondakova I.V. The characterization of exosomes from biological fluids of patients with different types of cancer. AIP Conference Proceedings 1882; 2017: 020080. doi: 10.1063/1.5001659.Yunusova N.V., Tamkovich S.N., Stakheeva M.N., Grigor’eva A.A., Somov A.K., Tugutova E.A., Kolomiets L.A., Molchanov S.V., Afanas’ev S.G., Kakurina G.V., Choinzonov E.L., Kondakova I.V. The characterization of exosomes from biological fluids of patients with different types of cancer. AIP Conference Proceedings 1882; 2017: 020080. doi: 10.1063/1.5001659.

The authors declare that there are no conflicts of interest present.